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HIV care continuum characteristics among
people with opioid use disorder and HIV in
Vietnam: baseline results from the BRAVO
study
Caroline King1,2*, Le Minh Giang3, Gavin Bart4, Lynn Kunkel5 and P. Todd Korthuis5,6
Abstract
Background: Little is known about patient characteristics that contribute to initiating antiretroviral therapy (ART)
and achieving viral suppression among HIV people with opioid use disorder in Vietnam. The primary objective of
this analysis was to evaluate associations between participant characteristics and the critical steps in the HIV care
continuum of ART initiation and HIV viral suppression among people with opioid use disorder and HIV in Vietnam.
Methods: We assessed baseline participant characteristics, ART status, and HIV viral suppression (HIV RNA PCR < 200
copies/mL) enrolled in a clinical trial of HIV clinic-based buprenorphine versus referral for methadone among
people with opioid use disorder in Vietnam. We developed logistic regression models to identify characteristics
associated with ART status and HIV viral suppression.
Results: Among 283 study participants, 191 (67.5%) were prescribed ART at baseline, and 168 of those on ART (90%)
were virally suppressed. Years since HIV diagnosis (aOR = 1.12, 95% CI 1.06, 1.19) and being married (aOR = 2.83, 95% CI
1.51, 5.34) were associated with an increased likelihood of current prescription for ART at baseline. Greater depression
symptoms were negatively associated with receipt of ART (aOR = 0.97, 95% CI = (0.94, 0.9963)). In the HIV suppression
model, once adjusting for all included covariates, only receipt of ART was associated with viral suppression (aOR = 25.9,
95% CI = (12.5, 53.8). In bivariate analyses, methamphetamine was negatively correlated with ART prescription (p = 0.07)
and viral suppression (p = 0.08).
Conclusion: While fewer than 90% of participants had received ART, 90% of those on ART had achieved HIV viral
suppression at baseline, suggesting that interventions to improve uptake of ART in Vietnam are essential for achieving
UNAIDS 90–90-90 goals in people who use heroin in Vietnam. Social determinants of health associated with ART and
HIV viral suppression suggest that social support may be a key to facilitating both of these steps in the HIV care continuum.
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Background
Opioid use disorder (OUD) and human immunodeficiency
virus (HIV) are intertwined epidemics worldwide; around
one-third of all new HIV infections outside of sub-Saharan
African occur among people who inject drugs [1, 2]. In
Vietnam, people who use drugs experience even higher
rates of HIV infection, with an estimated 60% of new HIV
cases occurring among people who inject drugs [3]. In
Vietnam, research is needed to explore what factors may
impact aspects of the HIV care continuum, including anti-
retroviral therapy (ART) initiation and viral suppression,
among people with opioid use disorder and HIV.
In 2014, the Joint United Nations Program on HIV/
AIDS released goals for HIV engagement and treatment
by 2020: that 90% of all people living with HIV will
know their status; 90% of all people diagnosed with HIV
will receive antiretroviral therapy; and 90% of those on
antiretroviral therapy will be virally suppressed [4]. Re-
cent literature highlights systems-level factors that im-
pact this care continuum in Vietnam, including the cost
of treatment [5], care coordination, chronic disease man-
agement, and peer networks [6]. However, little is
known about patient level factors that contribute to en-
gaging in the HIV care continuum in Vietnam.
The Vietnamese government has worked to provide
care through specialized yet separate clinics for HIV care
and OUD over the past 15 years [7]. Beginning in 2005,
Vietnam began providing antiretroviral therapy through
the U.S. President’s Emergency Funding for AIDS Relief
(PEPFAR) funding [7]. Today, of the approximately 250,
000 people living with HIV in Vietnam, nearly 120,000
people receive ART; approximately half of those on ART
now receive locally-funded care (versus external aid) [8].
Despite these gains, we extrapolate from these numbers
that at least 130,000 people living with HIV remain un-
connected or unengaged in care in Vietnam. Gaps re-
main in creating systems that identify, engage, and
retain patients with HIV in care that meets their needs.
Vietnamese efforts to address injection drug use are
multifaceted. For several decades, Vietnam has used com-
pulsory drug detention centers (known as 06 centers) to
curb substance use [9]. In 2008, Vietnam began to shift
from this model, building clinics to provide methadone
maintenance therapy (MMT) to people with opioid use
disorder [10]. Following the success of initial MMT pilot
demonstrations, the Vietnamese government expanded
MMT clinics to all provinces in Vietnam, creating access
to treatment for an estimated 50,000 people [10].
Over the past several years, changes in external aid
challenged Vietnam to identify how to continue to
provide HIV and opioid use disorder care in com-
munities. Research completed in 2016 found most
people with HIV and OUD in Vietnam prefer inte-
grated treatment, where they can receive both MMT
and ART at the same time [11]. Further data sug-
gested that addressing both HIV and opioid use dis-
order treatment can enhance HIV outcomes and
decrease behaviors that increase transmission risk
[12–14]. Over the last several years, Vietnam has
successfully piloted clinics that provide both HIV
and MMT.
To date, few studies have explored what individual
characteristics may contribute to viral suppression in
Vietnam regardless of opioid use. Several studies demon-
strate that comorbid substance use disorders can de-
crease the likelihood of HIV viral suppression [15, 16],
though the majority of this effect is likely related to so-
cial barriers rather than a physiologic mechanism. One
study found adherence to ART and use of trimetho-
prim/sulfamethoxazole as predictors of HIV viral sup-
pression, while a history of tuberculosis was a risk factor
for non-suppression [7]. In another study, younger age
at beginning of treatment and positive Hep-C antibody
were associated with virologic failure on HIV treatment
in Vietnam [17]. Social isolation, high perceived stigma,
and multiple daily pill regimens have also been associ-
ated with suboptimal HIV virologic suppression in
Vietnam [18]. The primary objective of this analysis was
to evaluate associations between participant characteris-
tics and the critical steps in the HIV care continuum of
ART initiation and HIV viral suppression (HIV-1 RNA
PCR < 200 copies/mL) among people with opioid use
disorder and HIV in Vietnam.
Methods
Study design and setting
This study reports cross-sectional baseline characteris-
tics of the Buprenorphine to Improve HIV Care Engage-
ment and Outcomes (BRAVO) Randomized Trial
(ClinicalTrials.gov NCT01936857). The BRAVO trial en-
rolled people with HIV and moderate-to-severe opiate
use disorder to receive either methadone maintenance
therapy (MMT) or buprenorphine/naloxone (BUP/NX)
at six Vietnamese HIV clinics between 2015 and 2019.
The study clinics were chosen in the epicenter of Viet-
nam’s HIV and opiate epidemics; four clinics are located
in Hanoi, one in Tanh Hoa Province, and one in Bac
Giang Province. Clinics were selected based on the high
prevalence of untreated opiate use disorder among newly
engaging people with a history of intravenous drug use,
ability to enroll sufficiently for the study, availability of
MMT, and support of local authorities.
This study was conducted in partnership with Hanoi
Medical University, the Provincial AIDS Control author-
ities of Hanoi, Thanh Hoa and Bac Giang, the Vietnam-
ese National Institute of Mental Health and Oregon
Health & Science University in Portland, Oregon.
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Consent and data collection
Research assistants reviewed the written Vietnamese lan-
guage informed consents with participants in a confiden-
tial space in the HIV clinic. Participants were instructed
their study participation had no bearing on HIV treatment
or other usual care at their clinic. Those agreeing to par-
ticipate signed the consent form which was securely filed.
Consents were periodically audited by the study quality as-
surance monitor for appropriate completion.
Research assistants administered surveys to partici-
pants in confidential settings using secured, web-based
electronic data entry. All survey instruments were ad-
ministered in Vietnamese and adapted for appropriate-
ness during previous research. Blood specimens for HIV
viral load PCR were collected at HIV clinics and sent to
the National Hospital for Tropical Diseases in Hanoi,
Vietnam for HIV-1 PCR testing using Abbott m2000rt
RealTime HIV-1 PCR amplification assay [19].
Participants
Participants were eligible for inclusion if they were HIV
positive, had current moderate-to-severe DSM-V opioid
use disorder (OUD), a positive urine drug screen for opi-
oids at the time of enrollment, interest in receiving treat-
ment for OUD, were age 18 or older, and were willing to
practice birth control, if female. Study research staff pri-
oritized patients new to HIV care or registered for care
but not receiving ART, though participants already re-
ceiving ART were allowed to enroll.
Participants were ineligible if they had a known hyper-
sensitivity to buprenorphine or naloxone, an aspartate
aminotransferase or alanine aminotransferase greater
than five times the upper limit of normal, were currently
pregnant or breastfeeding, had a serious medical or psy-
chiatric illness in the past 30 days that precluded safe
participation in the opinion of the study physician, or re-
ceived MMT within the past 30 days. Participants from
known vulnerable populations, including decisionally-
impaired adults, prisoners, and children, were also
excluded.
Measures
We assessed two critical steps in the HIV care continuum
as study outcome variables: 1) ART initiation at time of
enrollment, classified as a self-report of currently taking
ART at the time of study enrollment, and 2) HIV viral
suppression at time of enrollment, defined as HIV RNA
PCR < 200 copies/mL.
Participant characteristics included gender (male/fe-
male), greater than 9th grade education (yes/no), cur-
rently employed (yes/no), currently married (yes/no),
history of 06 rehabilitation (yes/no), substance use (posi-
tive urine drug screen (UDS) for methamphetamine or
amphetamine, methadone, or buprenorphine), and self-
reported daily tobacco use and risky alcohol use (defined
as an AUDIT-C score greater than 3 in women or
greater than 4 in men) [20–24]. Continuous covariates
included self-reported age, lifetime number of arrests,
years since HIV diagnosis, and the Depression Anxiety
Stress Scales (DASS) [25] scores for depression, anxiety




We assessed bivariate associations (t-tests, Pearson’s chi-
squared tests, and Fisher exact tests) of participant char-
acteristics and separately, ART initiation and HIV viral
suppression. Potential covariates were selected based on
a priori hypotheses and previous studies. We then con-
ducted bivariate analyses among those covariates and
the study outcome (viral suppression). We chose to in-
clude covariates in our model that had p-values of < 0.10
in bivariate analyses. Regardless of statistical significance,
we retained age and years since HIV diagnosis each final
model. Two separate multivariable logistic regression
models estimated the relationship of baseline participant
characteristics with study outcomes. We used an esti-
mated 10 events per degree of freedom ratio to estimate
the number of covariates we could include to avoid
overfitting [27]. We evaluated our continuous covariates
for linearity in the log-odds using Lowess scatter plots,
and also evaluated covariates for multi-collinearity, using
a cutoff of > 0.80 as a marker for covariate review. Fi-
nally, we used Hosmer-Lemeshow tests (p > 0.05) to
evaluate model goodness of fit. We dropped participants
missing both age and gender, and replaced the three par-
ticipants missing viral load at baseline as non-
suppressed.
Sensitivity analysis
After completing our primary analyses, we identified in-
fluential observations using Pregibon’s Delta-Beta statis-
tic and removed observations with a value greater than
0.20 from the model. If the directionality of associations
changed, we planned to report these results alongside
primary study results.
Results
Participant baseline characteristics are reported in
Table 1. Among the 283 study participants, most were
men (96.8%) who smoke every day (82.0%), and have
been arrested (82.7%) and sent to 06 rehabilitation at
least once (60.8%). Of those included, 67.5% (191 of 283)
were prescribed ART at baseline and 90% (168 of 191)
of those on ART were virally suppressed. An additional
6.0% (17 of 283) of people were virally suppressed, but
did not report taking ART, at baseline (Fig. 1).
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Table 1 Unadjusted and adjusted associations between baseline characteristics and ART prescription and viral suppression among




n = 191/273 (70.0%)
Virally suppressed









Mean Age (SD) 38.3 (6.1) p = 0.102
38.8 (6.0)
1.02 (0.97, 1.07) p = 0.02
38.8 (6.0)
1.04 (0.98, 1.10)
Gender (male) 274 (96.8%) – – – –
Greater than 9th grade education p = 0.86 – p = 0.84 –
Yes 115 (40.6%) 77 (40.3%) 76 (40.2%)
No 168 (59.4%) 114 (59.7%) 113 (60.0%)
Employed p = 0.31 – p = 0.12 –
Yes 130 (45.9%) 92 (48.2%) 93 (49.2%)
No 153 (54.1%) 99 (51.8%) 96 (50.8%)
Married p = 0.003 2.83 (1.51, 5.34) p = 0.004 1.44 (0.69, 3.03)
Yes 109 (38.5%) 85 (44.5%) 84 (44.4%)
No 174 (61.5%) 106 (55.5%) 105 (55.6%)
History of arrest (n = 280) – – – –
Yes 234 (82.7%)
No 46 (16.3%)
Lifetime number of arrests (n = 282) 2.2 (1.7) p = 0.13 2.3 (1.7) – p = 0.17 2.3 (1.7) –
History of 06 rehabilitation p = 0.03 1.58 (0.88, 2.85) p = 0.07 1.14 (0.55, 2.34)
Yes 172 (60.8%) 125 (65.4%) 112 (59.3%)
No 111 (39.2%) 66 (34.6%) 67 (35.4%)
Currently on ART (n = 273) – – p < 0.001 25.4 (12.13,
Yes 191 (67.5%) 168 (88.9%) 53.11)
No 92 (32.5%) 17 (9.0%)
Mean Years since HIV diagnosis (SD) 7.4 (5.7) p = < 0.0001
8.4 (5.4)
1.12 (1.06, 1.19) p = 0.002
8.1 (5.5)
0.99 (0.93, 1.06)
Mean CD4 cell count (SD) 405.0 (224.1) – – – –
Daily tobacco use p = 0.24 – p = 0.52 –
Yes 232 (82.0%) 154 (80.6%) 153 (81.0%)
No 51 (18.0%) 37 (19.4%) 36 (19.0%)
Risky alcohol use (n = 266) p = 0.14 – p = 0.41 –
Yes 90 (31.8%) 56 (29.3%) 53 (28.0%)
No 193 (68.2%) 126 (66.0%) 130 (68.8%)
Positive UDS for Methamphetaminesa p = 0.07 0.55 (0.28, 1.09) p = 0.08 0.74 (0.32, 1.70)
Yes 53 (18.7%) 31 (16.2%) 30 (15.9%)
No 230 (81.3%) 160 (83.8%) 159 (84.1%)
Positive UDS for methadone – – – –
Yes 4 (1.4%)
No 279 (98.6%)
Positive UDS for buprenorphine – – – –
Yes 1 (0.4%)
No 282 (99.6%)
DASS Anxiety Sub-score (SD) 4.5 (8.3) p = 0.77
4.42 (9.8)
– p = 0.99
4.48 (9.8)
–
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In bivariate analyses, increased age, number of years
since HIV diagnosis, being married, and a history of 06
rehabilitation were associated with being on ART at
study entry., while positive urine drug screen for meth-
amphetamine/amphetamines and increased DASS de-
pression sub-scores were associated lack of ART at
study entry. Similarly, age, being married, history of 06
rehabilitation, and being on ART were associated with
HIV viral suppression at study entry, while a positive
methamphetamine/amphetamine urine drug screen,
number of years since HIV diagnosis, and increased
DASS depression sub-score were associated with a lack
of HIV viral suppression at baseline (Table 1).
After adjusting for covariates, both years since HIV
diagnosis (aOR = 1.12, 95% CI 1.06, 1.19) and being mar-
ried (aOR = 2.83, 95% CI 1.51, 5.34) were associated with
increased odds of being on ART at baseline. A higher
DASS depression score was negatively associated with
being on ART (aOR = 0.97, 95% CI 0.94, 0.9963). In the
HIV viral suppression model, only current ART use
remained associated with viral suppression (aOR = 25.9,
95% CI 12.5, 53.8) after adjusting for covariates. None of
the sensitivity analyses identified changes in magnitude
or direction of associations.
Discussion
Our study indicates that the majority (67.5%) of people
with OUD and HIV enrolling in the BRAVO study had
already initiated ART at baseline; of those, 90% were vir-
ally suppressed, suggesting that further progress toward
achieving the UNAIDS goal of 90% with HIV viral sup-
pression in Vietnam hinges on increasing the proportion
of people receiving ART. Inclusion of ART receipt in
models of HIV viral suppression eclipsed the potential
effect of other participants characteristics, such as meth-
amphetamine use, supporting the WHO recommenda-
tion for offering ART to all persons living with HIV,
regardless of drug use.
Vietnam is working to identify ways to help support
people with HIV and co-occurring opioid use disorder
in ways that work for these patients [11]. Our study sug-
gests that once people are engaged in ART treatment,
achieving viral suppression is highly feasible. Interven-
tions to improve ART treatment initiation, such as inte-
grating OUD treatment in HIV treatment settings, are
urgently needed, particularly among those with shorter
times since HIV diagnosis.
Being married and time since HIV diagnosis were as-
sociated with already being prescribed ART at baseline;
increased depression symptoms were negatively associ-
ated with being on ART. The identification of marriage
as associated with increased ART treatment initiation
warrants further exploration into social supports and
their role in aiding HIV treatment. Marriage may be a
marker for greater social support in Vietnam, where the
social fabric is tightly woven; family life is central to so-
cial connectedness in Vietnam. Married participants may
also be responding to growing public health education
on the importance of taking ART to reduce the chances
of HIV transmission to uninfected partners [28]. To our
knowledge, similar results have not been reported in
Vietnam; however, research in China [29] and South
Table 1 Unadjusted and adjusted associations between baseline characteristics and ART prescription and viral suppression among




n = 191/273 (70.0%)
Virally suppressed









DASS Stress Sub-score (SD) 5.4 (12.1) p = 0.69
5.7 (14.4)
– p = 0.57
5.7 (14.5)
–
DASS Depression Sub-score (SD) 6.1 (10.2) p = 0.02
5.1 (7.3)
0.97 (0.94, 0.9963) p = 0.07
5.3 (7.4)
0.99 (0.96, 1.03)
aIncludes methamphetamines and amphetamines
Fig. 1 HIV care continuum among people with co-occurring opioid
use disorder, 2015 to 2019
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Africa [30] has shown that marriage may be positively
associated with ART initiation.
While depression is associated with suboptimal ART
adherence [31] [32], studies are mixed on its potential
association with ART initiation, with several studies
demonstrating an absence of association [33–37]. This
association has not, to our knowledge, been explored in
Vietnam to date. Authors working in China suggest that
subpopulations of patients with depression may have dif-
fering levels of ART initiation [36]; our study suggests
that patients with increased depression symptoms were
less likely to have initiated ART at baseline. This war-
rants further investigation, particularly as a recent study
in Vietnam showed that one-fifth of patients living with
HIV who were sampled endorsed depression symptoms
[38]. Improved mental health care access and engage-
ment may support goals for HIV treatment engagement
in Vietnam.
Among study participants, the strong association be-
tween ART receipt and HIV viral suppression eclipsed
other important participant characteristics associated
with HIV viral suppression in bivariate analysis, yet sug-
gests that increasing access to ART from 70% to the
UNAIDS target of greater than 90% is likely to achieve
HIV viral suppression in people who receives ART. This
study finding should not be interpreted as supporting
public health approaches that only support ART roll-out
without attention to substance use disorder treatment. Ra-
ther, it is essential to support ongoing opioid use disorder
prevention and treatment interventions in order to reduce
medical comorbidity and non-AIDS related deaths among
people with opioid use disorder who account for the ma-
jority of HIV infections in Vietnam [3]. Further research
regarding the potential role of strong social supports and
ART self-management practices in Vietnam may suggest
ways to improve HIV viral suppression among people
who inject drugs in other countries.
In bivariate analyses, age, marital status, and history of
06 rehabilitation were associated with viral suppression;
a positive methamphetamine/amphetamine urine drug
screen, years since HIV diagnosis, and increased DASS
depression sub-score were associated with decreased
odds of HIV viral suppression. Similarly to ART status,
marriage here may reflect the strong social connections
that are a pillar of Vietnamese culture. Studies in Italy
[39] and Russia [40] suggest that marriage was associ-
ated with viral suppression in these communities; this
may be because of the social support from these
relationships.
Studies primarily conducted in the United States have
demonstrated the negative association between co-
occurring methamphetamine use and viral suppression
[41–44]. Our finding in bivariate analyses maps onto this
body of literature, and warrants further investigation in
this potentially hard-to-reach population. Finally, higher
rates of depression have also been associated with de-
creased viral suppression [45, 46]. Improved mental
health care access and engagement may be critical in
meeting UNAIDS 90–90-90 goals.
Our study findings should be interpreted in light of
several potential limitations. First, we cannot make
causal inferences between participant characteristics as-
sociated with being on ART at baseline due to the
study’s cross-sectional design. Additional research is
needed to evaluate participants characteristics associated
with the HIV care continuum among this patient popu-
lation over time. Second, we were not able to consider
the many structural characteristics potentially associated
with being on ART or HIV viral suppression. The
BRAVO intervention, however, is a structural interven-
tion to increase access to OUD treatment in Vietnam
and will assessed prospectively. Third, Vietnam is a
middle-income country that has devoted substantial na-
tional resources to increasing treatment for both HIV
and OUD. Results may not be generalizable to countries
without such interventions, but may serve as a guide for
those wishing to expand care services.
Conclusions
This study provides a snapshot of Vietnam’s recent
strides to meet UNAIDS goals for HIV treatment initi-
ation and viral suppression by 2020. Future research
should identify additional patient-level factors associated
with aspects of the HIV care continuum among people
with opioid use disorder, including longitudinal inter-
ventions of integrated care models for treatment of HIV
and OUD.
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